Evidence map›Paper›PMID 26423951›Full record

ArticleJournal of virology2015

Comparison of the Life Cycles of Genetically Distant Species C and Species D Human Adenoviruses Ad6 and Ad26 in Human Cells.

Mallory A Turner, Sumit Middha, Sean E Hofherr, Michael A Barry

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mallory A TurnerVirology and Gene Therapy Program, Mayo Graduate School, Mayo Clinic, Rochester, Minnesota, USA.
Sumit MiddhaDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Sean E HofherrDivision of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Michael A BarryDivision of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA mab@mayo.edu.
Mayo Clinic · USMayo Clinic in Florida · US

Funding

Immunoevasive Mucosal Vaccines Against HIV-1R01AI096967 · NIAID · MAYO CLINIC ROCHESTER · PI BARRY, MICHAEL A · 2012 to 2016
$3.0M
Improving the Pharmacology of Oncolytic AdenovirusR01CA136945 · NCI · MAYO CLINIC ROCHESTER · PI BARRY, MICHAEL A · 2010 to 2014
$1.5M
NCI NIH HHS R01 CA136945NCI NIH HHS R01CA136945NIAID NIH HHS R01 AI096967
6 · The paper itself

Abstract

unlabelledOur understanding of adenovirus (Ad) biology is largely extrapolated from human species C Ad5. Most humans are immune to Ad5, so lower-seroprevalence viruses like human Ad6 and Ad26 are being tested as therapeutic vectors. Ad6 and Ad26 differ at the DNA level by 34%. To better understand how this might impact their biology, we examined the life cycle of the two viruses in human lung cells in vitro. Both viruses infected A549 cells with similar efficiencies, executed DNA replication with identical kinetics within 12 h, and began killing cells within 72 h. While Ad6-infected cells remained adherent until death, Ad26-infected cells detached within 12 h of infection but remained viable. Next-generation sequencing (NGS) of mRNA from infected cells demonstrated that viral transcripts constituted 1% of cellular mRNAs within 6 h and 8 to 16% within 12 h. Quantitative PCR and NGS revealed the activation of key early genes at 6 h and transition to late gene activation by 12 h by both viruses. There were marked differences in the balance of E1A and E1B activation by the two viruses and in the expression of E3 immune evasion mRNAs. Ad6 was markedly more effective at suppressing major histocompatibility complex class I (MHC I) display on the cell surface and in evading TRAIL-mediated apoptosis than was Ad26. These data demonstrate shared as well as divergent life cycles in these genetically distant human adenoviruses. An understanding of these differences expands the knowledge of alternative Ad species and may inform the selection of related Ads for therapeutic development. IMPORTANCE: A burgeoning number of adenoviruses (Ads) are being harnessed as therapeutics, yet the biology of these viruses is generally extrapolated from Ad2 and Ad5. Here, we are the first to compare the transcriptional programs of two genetically distant Ads by mRNA next-generation sequencing (NGS). Species C Ad6 and Ad26 are being pursued as lower-seroprevalence Ad vectors but differ at the DNA level by 34%. Head-to-head comparison in human lung cells by NGS revealed that the two viruses generally conform to our general understanding of the Ad transcriptional program. However, fine mapping revealed subtle and strong differences in how these two viruses execute these programs, including differences in the balance of E1A and E1B mRNAs and in E3 immune evasion genes. This suggests that not all adenoviruses behave like Ad2 and Ad5 and that they may have unique strategies to infect cells and evade the immune system.

Indexed as

AdenoviridaeCell LineDNA, ViralGene Expression Regulation, ViralHistocompatibility Antigens Class IHumansLungSpecies SpecificityVirus ReplicationDNA, ViralHistocompatibility Antigens Class I

Identifiers

PMID26423951
PMCPMC4665244
OpenAlexW1806174947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.